Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases

Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases

US Patent 10144733 · Granted Dec 4, 2018

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Heterocyclic amides as kinase inhibitors2022
1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostag2021
Heterocyclic amides as kinase inhibitors2021
Chemical compounds2020
Heterocyclic amides as kinase inhibitors2020
Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatme2019
Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatme2019
Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatme2019
Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatme2019
Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatme2019
Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatme2019
Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatme2019